Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study
| Autor: | Schultheis, B. *, Reuter, D., Ebert, M.P., Siveke, J., Kerkhoff, A., Berdel, W.E., Hofheinz, R., Behringer, D.M., Schmidt, W.E., Goker, E., De Dosso, S., Kneba, M., Yalcin, S., Overkamp, F., Schlegel, F., Dommach, M., Rohrberg, R., Steinmetz, T., Bulitta, M., Strumberg, D. |
|---|---|
| Zdroj: | In Annals of Oncology October 2017 28(10):2429-2435 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|